Screening for mitogen-activated protein kinase signalling pathway alterations in children and young adults with cancer or histiocytic disorders is feasible, but targeted therapy with selumetinib showed “limited efficacy” in this population, say the NCI-COG Pediatric MATCH trial investigators.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.